VolitionRx signs first human out licensing deal for APS

VolitionRx (VNRX) announced the signing of a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome, or APS, with Werfen’s Immunoassay Technology Center, a provider of specialized diagnostics. Full terms of the agreement are confidential. Under this agreement Werfen will gain access to the components of Volition’s proprietary Nu.Q H3.1 NETs assay and will investigate its clinical utility in the management of APS patients on its platforms. Werfen also has an option to negotiate terms with Volition for it to launch the product commercially under an exclusive license. Antiphospholipid syndrome or APS is a disorder of the immune system that causes an increased risk of blood clots.